Rifampin in CYP24A1-related Hypercalcemia and Hypercalciuria
Status:
Recruiting
Trial end date:
2030-12-01
Target enrollment:
Participant gender:
Summary
This study evaluates the efficacy of rifampin in the treatment of hypercalcemia and/or
hypercalciuria in participants with biallelic inactivating mutations of the CYP24A1 gene.
Eligible subjects will receive rifampin for a total of 16 weeks during this study.
Phase:
Phase 2
Details
Lead Sponsor:
Children's Hospital of Philadelphia
Collaborator:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)